Editorial & Columns Big Pharma: Expenditure on R&D and SG&A December 18, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Biocon opts for Full Integration of Biocon Biologics December 10, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Co-opetition in Action among Pharma MNCs December 5, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Eli Lilly entry in Trillion Dollar Club November 28, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Mixed Signals: Changing India-China Ties in Drugs & Pharma Trade November 20, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Domination of American and European Pharma MNCs November 13, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Mega deal in Global Consumer Health & Wellness: Kimberly-Clark to acquire Kenvue November 5, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns A Viewpoint on Bharat Sovereign Wealth Fund October 30, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns R&D Spending by Listed Pharma MNCs in India: A Concern October 22, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Trade Margins in Pharmaceutical Industry: Indian Experience October 16, 2025 | Dr. Anil Kumar Angrish | No Comments | More